TX-COGNITIVE-SPACE
Cognitive Space today announced it has been selected to participate in the Amazon Web Services (AWS) Space Accelerator , a business support program for startups seeking to use AWS to help solve the biggest challenges in the space industry. This opportunity will support Cognitive Space efforts to revolutionize satellite operations by bringing the power of artificial intelligence and machine learning to mission operations and collection planning. Cognitive Space provides New Space organizations with sophisticated tools for optimizing revenue and performance yield as their satellite constellations grow and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005120/en/
New for 2021, the four-week AWS Space Accelerator curriculum provides hands-on AWS Cloud and technical training, mentorship, coaching, and business support in collaboration with Seraphim, one of the world’s leading investment groups focused exclusively on the space industry, who will provide business development and investment guidance.
Cognitive Space will rely on AWS Cloud infrastructure for its own Space-focused software products - including licensed services, underlying platform architecture, development & test environments, and AI/ML training and processing workloads. Cognitive Space will take advantage of AWS services for scalability, cost-effectiveness, security, reliability, and global reach.
“Being one of the few startups accepted into the AWS Space Accelerator is a great honor and we appreciate the confidence AWS has placed in us,” said Scott Herman, CEO of Cognitive Space. “We’re very excited about the mentoring opportunity that the accelerator provides to startups like ours, and we look forward to working closely with AWS and Seraphim as we build our company.” Guy de Carufel, CTO of Cognitive Space, added “We depend on Amazon Web Services to provide high-reliability and scalable infrastructure for the satellite operations services we deliver to our customers and partners, and we are eager to learn more from the AWS experts during the accelerator.”
As one of 10 companies chosen for this opportunity out of a field of approximately 200 startups, Cognitive Space will receive up to $100,000 in AWS Activate credit, AWS Cloud training and support, mentorship, and additional business development resources including opportunities to speak with space-savvy venture investors.
“AWS looks forward to collaborating with our finalists to advance their inspiring vision for transforming how we understand, operate in, and benefit from space,” said Clint Crosier, director of the Aerospace and Satellite business at AWS. “Congratulations to our finalists, who were selected from hundreds of impressive startups from across the global space industry. The cloud is uniquely suited to spur the success of space companies in so many ways, and we are excited to help these companies achieve their biggest goals.”
Proposals were judged on several factors including the innovative and unique nature of the project, the overall value the solution will bring to the space industry, the creative application of AWS to solve problems, and the team’s ability to deliver on its specific mission.
For more information on the AWS Space Accelerator, visit https://seraphim.vc/aws/accelerator/ .
About Cognitive Space
Cognitive Space is developing advanced automation systems for the space industry with a particular focus on the software management of satellite constellations, including mission management, collection planning, communication link management, and modeling & simulation of future capabilities.
Our early focus is on orchestrated collection management for the explosion of new remote sensing constellations - multi-phenomenology, large-fleet constellations of small satellite sensors that offer unprecedented facility monitoring, activity monitoring, and pattern-of-life analysis for national security and commercial organizations with a global monitoring mission.
Cognitive Space is developing an AI-driven solution for near real-time dynamic mission planning for Low Earth Orbit (LEO) Satellites. By 2030, research analysts predict 15-20x growth in deployed satellites in service, from 3000 in 2021 to ~50,000 satellites in orbit. Satellite constellations are increasingly being tasked by government and commercial consumers for use cases including communications, agriculture, environmental protection, meteorology, navigation, national defense, and myriad other commercial, military and governmental use cases.
The Cognitive Space satellite constellation management platform allows operators to reduce command and control lead time, reduce human errors and streamline satellite asset integration. For commercial operators this allows them to maximize service capacity, increase revenue and margin, and optimize performance yield. Cognitive Space’s platform is multi-purpose, serving the needs of the Federal Government, US Department of Defense and commercial enterprises.
More information about Cognitive Space can be found at http://www.cognitivespace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom